Simultaneously, we showed SpiD3 treatment induced extracellular ATP and HMGB1 release from both HG-3 and OSU-CLL cells in a dose- and time-dependent fashion. The gene discussed is HMGB1; the disease is B-cell chronic lymphocytic leukemia.